Prospective Evaluation Of FDG PET/CT As A Predictor Of Prognosis In Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

被引：0

作者：

Nanni, C. ^{[1
]}

Zamagni, E. ^{[1
]}

Versari, A. ^{[2
]}

Chauvie, S. ^{[3
]}

Tacchetti, P. ^{[1
]}

Pantani, L. ^{[1
]}

Bianchi, A. ^{[3
]}

Rensi, M. ^{[4
]}

Bello, M. ^{[5
]}

Gallamini, A. ^{[6
]}

Patriarca, F. ^{[1
]}

Bertone, E. ^{[3
]}

Zannetti, B. ^{[1
]}

Boccadoro, M. ^{[7
]}

Cavo, M. ^{[1
]}

Fanti, S. ^{[1
]}

机构：

[1] AOU S Orsola Malpighi, Bologna, Italy

[2] Santa Maria Nuova Hosp, IRCSS, Reggio Emilia, Italy

[3] Santa Croce & Carle Hosp, Cuneo, Italy

[4] AOU S Maria Misericordia, Udine, Italy

[5] AO Citta Salute & Sci, Turin, Italy

[6] Lacassagne Canc Ctr, Res & Innovat Dept, Nice, France

[7] Univ Torino, Turin, Italy

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

OP-243

引用

页码：S82 / S83

页数：2

共 50 条

[21] Management of induction failures in newly diagnosed transplant-eligible multiple myeloma
Gertz, Morie A.
LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 1 - 3
[22] Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Bobin, Arthur
Kyheng, Maeva
Guidez, Stephanie
Gruchet-Merouze, Cecile
Richez, Valentine
Duhamel, Alain
Karlin, Lionel
Kolb, Brigitte
Tiab, Mourad
Araujo, Carla
Meuleman, Nathalie
Malfuson, Jean-Valere
Bourquard, Pascal
Lenain, Pascal
Perrot, Aurore
Roussel, Murielle
Jaccard, Arnaud
Petillon, Marie-Odile
Belhadj-Merzoug, Karim
Chretien, Marie-Lorraine
Fontan, Jean
Rodon, Philippe
Schmitt, Anna
Offner, Fritz
Voillat, Laurent
Cereja, Sophie
Kuhnowski, Frederique
Rigaudeau, Sophie
Decaux, Olivier
Humbrecht-Kraut, Catherine
Frayfer, Jamile
Fitoussi, Olivier
Roos-Weil, Damien
Eisenmann, Jean Claude
Dorvaux, Veronique
Voog, Eric G.
Moreau, Philippe
Avet-Loiseau, Herve
Hulin, Cyrille
Facon, Thierry
Leleu, Xavier
LEUKEMIA, 2022, 36 (03) : 881 - 884
[23] Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Arthur Bobin
Maéva Kyheng
Stéphanie Guidez
Cécile Gruchet-Merouze
Valentine Richez
Alain Duhamel
Lionel Karlin
Brigitte Kolb
Mourad Tiab
Carla Araujo
Nathalie Meuleman
Jean-Valère Malfuson
Pascal Bourquard
Pascal Lenain
Aurore Perrot
Murielle Roussel
Arnaud Jaccard
Marie-Odile Petillon
Karim Belhadj-Merzoug
Marie-Lorraine Chretien
Jean Fontan
Philippe Rodon
Anna Schmitt
Fritz Offner
Laurent Voillat
Sophie Cereja
Frédérique Kuhnowski
Sophie Rigaudeau
Olivier Decaux
Catherine Humbrecht-Kraut
Jamile Frayfer
Olivier Fitoussi
Damien Roos-Weil
Jean Claude Eisenmann
Véronique Dorvaux
Eric G. Voog
Philippe Moreau
Hervé Avet-Loiseau
Cyrille Hulin
Thierry Facon
Xavier Leleu
Leukemia, 2022, 36 : 881 - 884
[24] The Role of 18F-FDG-PET/CT Imaging in Predicting Outcome of Patients with Newly Diagnosed Multiple Myeloma
Mena, Esther
Lindenberg, Maria Liza
Turkbey, Ismail
Adler, Stephen
Eclarinal, Philip
McKinney, Yolanda
Weaver, Juanita
Choyke, Peter
Kazandjian, Dickran
JOURNAL OF NUCLEAR MEDICINE, 2021, 62
[25] Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub- study of the FORTE trial
Zamagni, Elena
Oliva, Stefania
Gay, Francesca
Capra, Andrea
Rota-Scalabrini, Delia
D'Agostino, Mattia
Belotti, Angelo
Galli, Monica
Racca, Manuela
Zambello, Renato
Gamberi, Barbara
Albano, Domenico
Bertamini, Luca
Versari, Annibale
Grasso, Mariella
Sgherza, Nicola
Priola, Claudia
Fioritoni, Francesca
Patriarca, Francesca
De Cicco, Gabriella
Villanova, Tania
Pascarella, Anna
Zucchetta, Pietro
Tacchetti, Paola
Fanti, Stefano
Mancuso, Katia
Barbato, Simona
Boccadoro, Mario
Musto, Pellegrino
Cavo, Michele
Nanni, Cristina
ECLINICALMEDICINE, 2023, 60
[26] Burden of CRAB Events By Relapse in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem Cell Transplant
Pandya, Shivani
Clancy, Zoe
Shrestha, Sulena
Wang, Li
Baser, Onur
BLOOD, 2018, 132
[27] Newly diagnosed Multiple Myeloma Daratumumab-Rd - a Standard for non-transplant Eligible Patients
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06) : 380 - 381
[28] SUBCUTANEOUS BORTEZOMIB CONTAINING REGIMENS AS UPFRONT TREATMENT OF NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
Rizzello, I.
Zamagni, E.
Dozza, L.
Quaresima, M.
Petrucci, M. T.
De Stefano, V.
Antonioli, E.
Tosi, P.
D'Agostino, M.
Offidani, M.
Gozzetti, A.
Rivoli, G.
Testoni, N.
Martello, M.
Tacchetti, P.
Pantani, L.
Mancuso, K.
Rocchi, S.
Caratozzolo, I.
Cavo, M.
HAEMATOLOGICA, 2019, 104 : 117 - 117
[29] Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
Gay, Francesca
Musto, Pellegrino
Scalabrini, Delia Rota
Galli, Monica
Belotti, Angelo
Zamagni, Elena
Bertamini, Luca
Zambello, Renato
Quaresima, Micol
De Sabbata, Giovanni
Pietrantuono, Giuseppe
D'Agostino, Mattia
Oddolo, Daniela
Capra, Andrea
Liberati, Anna Marina
Palmieri, Salvatore
Narni, Franco
Offidani, Massimo
Cavo, Michele
Boccadoro, Mario
BLOOD, 2020, 136
[30] Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand
Chien, Nicole
Romeril, Ken
Baker, Bart
Goodman, Hugh
Chan, Henry
NEW ZEALAND MEDICAL JOURNAL, 2020, 133 (1527) : 104 - 110

← 1 2 3 4 5 →